Edesa Biotech Change in Accounts Payable 2013-2025 | EDSA

Edesa Biotech change in accounts payable from 2013 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Edesa Biotech Change in Accounts Payable 2013-2025 | EDSA

Edesa Biotech change in accounts payable from 2013 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$246.7B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100.2B
Bristol Myers Squibb (BMY)$98.4B
GSK (GSK)$80.7B
CSL (CSLLY)$70.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.2B
Insmed (INSM)$26.9B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.7B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15.3B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.9B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.2B
Roivant Sciences (ROIV)$8B